Control of cell migration: a tumour suppressor function for p53?

Much remains to be learned about how cancer cells acquire the property of migration, a prerequisite for invasiveness and metastasis. Loss of p53 functions is assumed to be a crucial step in the development of many types of cancers, leading to dysregulation of cell cycle checkpoint controls and apoptosis. However, emerging evidence shows that the contribution of the tumour suppressor p53 to the control of tumorigenesis is not restricted to its well‐known anti‐proliferative activities, but is extended to other stages of cancer development, i.e. the modulation of cell migration. This interesting alternative function has been proposed in light of the effect of p53 on specific features of migrating cells, including cell spreading, establishment of cell polarization and the production of protrusions. The effects of p53 on cell motility are largely mediated through the regulation of Rho signalling, thereby controlling actin cytoskeletal organization. These recent studies connect the regulation of proliferation to the control of cell migration and define a new concept of p53 function as a tumour suppressor gene, suggesting that p53 might be involved in tumour invasion and metastasis. This review focuses on emerging data concerning the properties of p53 that contribute to its atypical role in the regulation of cell migration.

[1]  B. Kaina,et al.  Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters , 2002, British Journal of Cancer.

[2]  J. Dixon,et al.  PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.

[3]  P. Steeg.  Metastasis suppressors alter the signal transduction of cancer cells , 2003, Nature Reviews Cancer.

[4]  L. Donehower,et al.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors , 1993, Cell.

[5]  Dan L. Sackett,et al.  p53 is associated with cellular microtubules and is transported to the nucleus by dynein , 2000, Nature Cell Biology.

[6]  H. Fujiwara,et al.  A Definitive Role of RhoC in Metastasis of Orthotopic Lung Cancer in Mice , 2004, Clinical Cancer Research.

[7]  H. Varmus,et al.  The Absence of p53 Promotes Metastasis in a Novel Somatic Mouse Model for Hepatocellular Carcinoma , 2005, Molecular and Cellular Biology.

[8]  F. McCormick,et al.  A role for Rho in Ras transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[10]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[11]  René Bernards,et al.  A progression puzzle. , 2002, Nature.

[12]  A. Levine,et al.  Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  W. Deppert,et al.  Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (Vimentin) scaffold , 1998, Oncogene.

[14]  L. Chodosh,et al.  Microarray Expression Profiling of p53-Dependent Transcriptional Changes in an Immortalized Mouse Embryo Fibroblast Cell Line , 2003, Cancer biology & therapy.

[15]  M. Buendia.  Genetics of hepatocellular carcinoma. , 2000, Seminars in cancer biology.

[16]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[17]  Kenneth M. Yamada,et al.  Taking Cell-Matrix Adhesions to the Third Dimension , 2001, Science.

[18]  V. Iotsova,et al.  Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[20]  D. Mukhopadhyay,et al.  Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.

[21]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[22]  Y. Haupt,et al.  p53: An Internal Investigation , 2002, Cell cycle.

[23]  T. Katsumoto,et al.  Cell‐cycle dependent biosynthesis and localization of p53 protein in untransformed human cells , 1995, Biology of the cell.

[24]  Amanda Y. Chan,et al.  Rho Family GTPases Regulate Mammary Epithelium Cell Growth and Metastasis Through Distinguishable Pathways , 2001, Molecular medicine.

[25]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[26]  John G. Collard,et al.  A role for Rac in Tiaml-induced membrane ruffling and invasion , 1995, Nature.

[27]  A. Hall,et al.  Cdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity , 2003, Nature.

[28]  James M. Roberts,et al.  Regulation of the cytoskeleton: an oncogenic function for cdk inhibitors? , 2004, Nature Reviews Cancer.

[29]  T. Nikaido,et al.  Up-Regulation of Small GTPases, RhoA and RhoC, Is Associated with Tumor Progression in Ovarian Carcinoma , 2003, Laboratory Investigation.

[30]  T. Lawrence,et al.  Global Genechip Profiling to Identify Genes Responsive to p53-Induced Growth Arrest and Apoptosis in Human Lung Carcinoma Cells , 2003, Cancer biology & therapy.

[31]  A. Hall,et al.  Integrin-Mediated Activation of Cdc42 Controls Cell Polarity in Migrating Astrocytes through PKCζ , 2001, Cell.

[32]  S. Merajver,et al.  Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. , 2002, The American journal of pathology.

[33]  Pierre Roux,et al.  TNFα induces sequential activation of Cdc42- and p38/p53-dependent pathways that antagonistically regulate filopodia formation , 2004, Journal of Cell Science.

[34]  Stephen N. Jones,et al.  p53 mutant mice that display early ageing-associated phenotypes , 2002, Nature.

[35]  J. Boerner,et al.  Activation of Rho Is Required for Ligand-independent Oncogenic Signaling by a Mutant Epidermal Growth Factor Receptor* , 2001, The Journal of Biological Chemistry.

[36]  J. Fraumeni,et al.  Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. , 1969, Journal of the National Cancer Institute.

[37]  R. Jope,et al.  Nuclear accumulation of glycogen synthase kinase‐3 during replicative senescence of human fibroblasts , 2004, Aging cell.

[38]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[39]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[40]  K. A. Comer,et al.  Human smooth muscle α-actin gene is a transcriptional target of the p53 tumor suppressor protein , 1998, Oncogene.

[41]  S. Lowe,et al.  Dissecting p53 tumor suppressor functions in vivo. , 2002, Cancer cell.

[42]  M. Nakamoto,et al.  K-ras and rho A mutations in malignant pleural effusion. , 2001, International journal of oncology.

[43]  Shuh Narumiya,et al.  An essential part for Rho–associated kinase in the transcellular invasion of tumor cells , 1999, Nature Medicine.

[44]  S. Gupta,et al.  Activation of small GTPase Rho is required for autocrine motility factor signaling. , 2002, Cancer research.

[45]  John G. Collard,et al.  Role of Rho-family proteins in cell adhesion and cancer. , 2003, Current opinion in cell biology.

[46]  Yi Zheng,et al.  Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion , 2004, Oncogene.

[47]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[48]  Y. Sun,et al.  p53 Down-regulates Human Matrix Metalloproteinase-1 (Collagenase-1) Gene Expression* , 1999, The Journal of Biological Chemistry.

[49]  Kenneth M. Yamada,et al.  Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. , 2001, Journal of cell science.

[50]  W. Linehan,et al.  Examination of human tumors for rhoA mutations. , 1994, Oncogene.

[51]  S. Narumiya,et al.  Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. , 1998, British Journal of Cancer.

[52]  Ling Song,et al.  Glycogen Synthase Kinase-3β (GSK3β) Binds to and Promotes the Actions of p53* , 2003, Journal of Biological Chemistry.

[53]  G. Getz,et al.  DNA microarrays identification of primary and secondary target genes regulated by p53 , 2001, Oncogene.

[54]  J. Vasiliev,et al.  Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes , 1997, Oncogene.

[55]  J. Vasiliev,et al.  Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization , 2000, Oncogene.

[56]  James M. Roberts,et al.  p27Kip1 modulates cell migration through the regulation of RhoA activation. , 2004, Genes & development.

[57]  John G. Collard,et al.  Rho-like GTPases in tumor cell invasion. , 2000, Methods in enzymology.

[58]  L. Peso,et al.  Rho proteins induce metastatic properties in vivo , 1997, Oncogene.

[59]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[60]  Weiqun Li,et al.  Differential Requirement for Rho Family GTPases in an Oncogenic Insulin-like Growth Factor-I Receptor-induced Cell Transformation* , 2001, The Journal of Biological Chemistry.

[61]  K. Vousden,et al.  Activation and activities of the p53 tumour suppressor protein , 2001, British Journal of Cancer.

[62]  G. Radda,et al.  Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter. , 1997, Nucleic acids research.

[63]  Luquan Wang,et al.  Generation of p53 target database via integration of microarray and global p53 DNA-binding site analysis. , 2004, Methods in molecular biology.

[64]  A. Giaccia,et al.  The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.

[65]  E. Lengyel,et al.  Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b , 2000, Oncogene.

[66]  M. Kapoor,et al.  High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  V. Braga,et al.  Tumor progression: Small GTPases and loss of cell-cell adhesion. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[68]  N. Masuyama,et al.  Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells , 2001, Current Biology.

[69]  J. Camonis,et al.  Mutation status of genes encoding RhoA, Rac1, and Cdc42 GTPases in a panel of invasive human colorectal and breast tumors , 2001, Journal of Cancer Research and Clinical Oncology.

[70]  B. Kaina,et al.  Rho GTPases are over‐expressed in human tumors , 1999, International journal of cancer.

[71]  M. Barone,et al.  RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho , 2001, Oncogene.

[72]  M. Kubbutat,et al.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability , 1997, Molecular and cellular biology.

[73]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[74]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[75]  J. Milner,et al.  The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage , 2002, Oncogene.

[76]  Brian Pope,et al.  Wild-type p53 protein shows calcium-dependent binding to F-actin , 1999, Oncogene.

[77]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[78]  A. Inoue,et al.  Senescence-associated alterations of cytoskeleton: extraordinary production of vimentin that anchors cytoplasmic p53 in senescent human fibroblasts , 2005, Histochemistry and Cell Biology.

[79]  S. Etienne-Manneville,et al.  Cdc42 - the centre of polarity , 2004, Journal of Cell Science.

[80]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[81]  Luquan Wang,et al.  Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression , 2003, Oncogene.

[82]  N. Mantel,et al.  Cancer mortality among chemists. , 1969, Journal of the National Cancer Institute.

[83]  H. Bruch,et al.  Acceleration of Cutaneous Wound Healing by Transient p53 Inhibition , 2002, Laboratory Investigation.

[84]  P. Roux,et al.  The small GTPases Cdc42Hs, Rac1 and RhoG delineate Raf-independent pathways that cooperate to transform NIH3T3 cells , 1997, Current Biology.

[85]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[86]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[87]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.

[88]  P. Roux,et al.  Regulation of Cdc42‐mediated morphological effects: a novel function for p53 , 2002, The EMBO journal.

[89]  A. Hall,et al.  Rho GTPases in transformation and metastasis. , 2002, Advances in cancer research.

[90]  J. Seyer,et al.  Macrophages Are a Major Source Offibrogenic Factors That Stimulation of Fibroblast Chemotaxis by Human Recombinant Tumor Necrosis Factor a (tnf-cx) and a Synthetic Tnf-a 31-68 Peptide , 2022 .

[91]  Rotter,et al.  Meth A fibrosarcoma cells express two transforming mutant p53 species. , 1988, Oncogene.

[92]  J. Seyer,et al.  Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide , 1990, The Journal of experimental medicine.

[93]  H. Antoniades,et al.  p53 expression during normal tissue regeneration in response to acute cutaneous injury in swine. , 1994, The Journal of clinical investigation.

[94]  Yi Zheng,et al.  Involvement of Rho Family GTPases in p19Arf- and p53-Mediated Proliferation of Primary Mouse Embryonic Fibroblasts , 2004, Molecular and Cellular Biology.

[95]  F. McCormick,et al.  An essential role for Rac in Ras transformation , 1995, Nature.

[96]  J. Deddens,et al.  Pak-1 Expression Increases with Progression of Colorectal Carcinomas to Metastasis , 2004, Clinical Cancer Research.

[97]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[98]  L. Donehower,et al.  Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. , 1995, Oncogene.

[99]  Erik Sahai,et al.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis , 2003, Nature Cell Biology.

[100]  W. Woods,et al.  PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. , 2003, Cancer research.

[101]  C. Sherr,et al.  Principles of Tumor Suppression , 2004, Cell.

[102]  Kyoko Arai,et al.  Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[103]  P. Kleihues,et al.  Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.

[104]  F. McCormick,et al.  Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation , 1997, Molecular and cellular biology.

[105]  Yi Zheng,et al.  p19Arf-p53 Tumor Suppressor Pathway Regulates Cell Motility by Suppression of Phosphoinositide 3-Kinase and Rac1 GTPase Activities* , 2003, The Journal of Biological Chemistry.

[106]  K. Harms,et al.  The C Terminus of p53 Family Proteins Is a Cell Fate Determinant , 2005, Molecular and Cellular Biology.